Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

5.320 +0.190 (+3.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Precision BioSciences to Participate in Upcoming Jefferies Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Appoints Melinda Brown to Board of Directors
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Appoints Juli Blanche as Chief People Officer
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Completes Spin-Out of Elo Life Systems
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meeting of the American Society of Hematology
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 27, 2021
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Appoints Michael Amoroso Chief Executive Officer
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.